Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study) by Buljubasic, Nermina et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/206268
 
 
 
Please be advised that this information was generated on 2020-09-08 and may be subject to
change.
Temporal Pattern of Growth Differentiation Factor-15
Protein After Acute Coronary Syndrome
(From the BIOMArCS Study)
Nermina Buljubasic, MDa, Maxime M. Vroegindewey, BSca, Rohit M. Oemrawsingh, MDa,
Folkert W. Asselbergs, MD, PhDb, Etienne Cramer, MDc, Anho Liem, MD, PhDd,
Pim van der Harst, MD, PhDe, Arthur Maas, MDf, Eelko Ronner, MD, PhDg, Carl Schotborgh, MDh,
Alexander J. Wardeh, MD, PhDi, K. Martijn Akkerhuis, MD, PhDa, and Eric Boersma, MSc, PhDa,*, for
the BIOMArCS investigators
Growth differentiation factor-15 (GDF-15) has appeared as a promising biomarker with
strong predictive abilities in acute coronary syndrome (ACS). However, studies are solely
based on single measurements in the acute phase of an ACS event. The way GDF-15 pat-
terns in post-ACS patients behave on the long term is largely unknown. We conducted a
nested case-control study within our multicenter, prospective, observational biomarker
study (BIOMArCS) of 844 ACS patients. Following an index ACS event, high-frequency
blood sampling was performed during 1-year of follow-up. GDF-15 was determined
batchwise by electrochemiluminescence immunoassays in 37 cases with a recurrent event
during 1-year follow-up, and in 74 event-free controls. Cases and controls had a mean §
standard deviation age of 66.9 § 11.3 years and 81% were men. From 30 days onwards,
patients showed stable levels, which were on average 333 (95% confidence interval 68 to
647) pg/mL higher in cases than controls (1704 vs 1371 pg/mL; p value 0.013). Addition-
ally, in the post 30-day period, GDF-15 showed low within-individual variability in both
cases and controls. In conclusion, post-ACS patients experiencing a recurrent event had
stable and systematically higher GDF-15 levels during 30-day to 1-year follow-up than
their event-free counterparts with otherwise similar clinical characteristics. Thus, postdi-
scharge blood sampling might be used throughout the course of 1 year to improve prog-
nostication, whereas, in view of the low within-individual variation, the number of
repeated sampling moments might be limited. © 2020 The Authors. Published by Elsev-
ier Inc. This is an open access article under the CC BY license. (http://creativecommons.
org/licenses/by/4.0/) (Am J Cardiol 2019;124:8−13)
In recent years, circulating growth differentiation factor-
15 (GDF-15), a stress-induced cytokine, has emerged as a
biomarker of interest due to its potential prognostic value
in patients with cardiovascular disease.1 In particular, ele-
vated levels of GDF-15 are associated with an impaired
prognosis after acute coronary syndromes (ACS).2-6 How-
ever, the prognostic value of GDF-15 in ACS patients thus
far, has been mainly based on single measurements in the
early, acute phase of an acute ischemic event. Therefore,
the optimal time point in the stabilized post-ACS phase for
GDF-15 blood sampling to make prognostic implications
remains not fully elucidated yet. We used our ‘BIOMarker
study to identify the Acute risk of a Coronary Syndrome’
(BIOMArCS) with high-frequency blood sampling in post-
ACS patients as a platform to describe the temporal evolu-
tion of GDF-15 during 1-year follow-up, to evaluate differ-
ences between patients with and without a recurrent event,
and to study the individual variability of GDF-15.
Methods
We performed a nested case-control analysis within the
main BIOMArCS study that was approved by the medical
ethics committees of all participating hospitals. The rationale
and design of BIOMArCS are described in detail elsewhere.7
In brief, BIOMArCS is a prospective, multicenter, observa-
tional study conducted in 18 participating hospitals in the
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Netherlands. A total of 844 patients, admitted for an ACS,
including unstable angina pectoris, non−ST-elevation myo-
cardial infarction (NSTEMI) and ST-elevation myocardial
infarction (STEMI) and with at least one additional cardio-
vascular risk factor, were enrolled between 2008 and 2015.
Patients underwent regular blood sampling after the initial
admission for ACS according to a strict schedule to describe
the temporal evolution of blood biomarkers in the post-ACS
phase, and to reveal deviations in temporal biomarker pat-
terns before a recurrent coronary event. Venepuncture was
performed at admission, at hospital discharge and subse-
quently every fortnight during the first half year, followed by
monthly blood sample collection until 1 year. Follow-up
blood sampling was terminated permanently after coronary
artery bypass grafting, hospital admission for heart failure, or
a deterioration of renal function leading to a glomerular filtra-
tion rate of <30 mL/min/1.73 m2, since these conditions
influence circulating biomarker concentrations. Ultimately,
patients had 17 (median) repeated blood samples within 1
year. The study was performed in accordance with the criteria
described in the declaration of Helsinki and all patients pro-
vided written informed consent for their participation.
The primary study endpoint was a composite of cardiac
death, nonfatal myocardial infarction, or unstable angina
pectoris, requiring urgent coronary revascularization within
1-year follow-up. Study endpoints were adjudicated by a
clinical event committee, blinded for any biomarker data,
after the study was completed in 2015. In 2014, Roche
Diagnostics GmbH offered the opportunity to determine
GDF-15 with their precommercial assay in a limited num-
ber of BIOMArCS patients. Since no commercial GDF-15
assay would have been available within the foreseeable
future, we decided to accept this one-time offer. We ana-
lyzed the blood samples of all patients with an investigator-
reported endpoint event at that time, as well as 2 matched
endpoint-free controls for each such event. Matching was
based on admission hospital, age (§ 5 year range), gender,
diabetes mellitus, peripheral artery disease, and history of
coronary artery disease (CAD). We kept the results unana-
lyzed until study completion and event-adjudication. After
study completion, it appeared that 37 of the investigator-
reported events were confirmed as study endpoint. In the
current analysis, these events were included as cases,
together with their corresponding 74 matched controls.
Blood samples were initially handled and securely stored
on-site. Aliquots were frozen at ¡80˚C within 2 hours after
withdrawal. Long-term storage and batchwise GDF-15 analy-
sis took place at the Department of Clinical Chemistry of the
Erasmus MC, Rotterdam (the Netherlands). Laboratory per-
sonnel were blinded for any clinical data, including endpoint
data. The plasma GDF-15 concentrations were measured
using the quantitative sandwich electrochemiluminescence
immunoassay “ECLIA” (Roche Diagnostics, Mannheim,
Germany) on a Cobas e601 immunoassay analyzer. The low-
est detection limit of GDF-15 analyte concentration was
400 pg/mL. No interference was found using in vitro tests to
determine interference between 51 commonly used cardio-
vascular pharmaceuticals and the assay.
It is important to discern a fixed amount of individual
biomarker variability from clinically relevant changes over
time. Therefore certain parameters have been described to
define individual variability, which are needed to interpret
the relevance of changes of repeated measurements. The
coefficient of variation (CV) of a series of measurements is
defined as 100% times the standard deviation (sd) of the
measurements divided by their mean value (X):
CV ¼ 100%  sd=X
According to the methods by Fraser and Harris,8 the total
variation of a series of repeated measurements in individual
subjects can be split in 3 components, which represent the
variation due to the imprecision of the analytical process
(CVa), the intra-individual or within-subject variation
(CVi), and the inter-individual or between-subject variation
(CVg). CVa of GDF-15 in our laboratory appeared to be
1.75% and 1.88% for high and low concentrations, respec-
tively. Subsequently, CVi was defined as the median value
of the CVs of the repeated measurements in individual sub-
jects (CVsubject), adjusted for the analytical variation:
CVi ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
medianðCV2subjectÞCV2a
q
Finally, CVg was determined as 100% times the standard
deviation (sdXsubject ) of the mean values of the repeated
measurements in individual subjects (Xsubject) by the
(unweighted) mean of these means (Xgroup):
CVg ¼ 100%  sdXsubject=Xgroup
The Index of Individuality (II) is the ratio of the com-
bined within-subject and analytical variation relative to the
between-subject variation:
II ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
CV2i þ CV2a
q
=CVg
Since a high II (>1.4) indicates a relatively high within-
subject variation and low between-subject variation, it is
more likely that an unusual biomarker value will lie outside
the borders of most overlapping values and therefore popu-
lation-based reference intervals are sufficient. Conversely,
when the II is low (<0.6), it is agreed that subjects should
have their own reference values, based on previous sam-
ples. The Reference Change Value (RCV) reflects the limit
of (relative) change in biomarker values in individual sub-
jects that can be explained by the combined within-subject
and analytical variation. For biomarkers with a skewed dis-
tribution a log-normal approach has been described, and
the RCV limits can be determined as follows:
RCVdownward ¼ eZa=2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2ln CV2iþCV2aþ1ð Þ
p
 1
RCVupward ¼ eZa=2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2ln CV2iþCV2aþ1ð Þ
p
 1
We used a = 0.05 (for 95% confidence), thus
Z0.025 = 1.96.
Since GDF-15 is known to be initially elevated post-
ACS, all aforementioned variability parameters are based
on >30 day blood samples. Although the exact pathophysi-
ological substrate for an initial elevation of GDF-15 in the
acute phase of ACS is unknown,9 a possible "washout"
effect due to an acute phase reaction is thereby hampered.
After that period, biochemical as well as clinical
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stabilization is expected to be reached for adequately deter-
mining GDF-15 variability. Thereafter, only patients with
at least 3 available measurements in that time window are
included, leaving 20 cases and 46 controls for variability
analysis.
Categorical data are presented as numbers and percen-
tages. Continuous variables are presented as mean § stan-
dard deviation (SD) or as median and interquartile range
(IQR), depending on their distribution. Normality of contin-
uous variables was examined by visual inspection of the
histogram and by normal Q-Q plots. The examined bio-
marker GDF-15 (outcome) showed a skewed distribution
and was therefore 2log-transformed for further analyses.
GDF-15 biomarker trajectories were examined across dif-
ferent follow-up time intervals after the ACS index event
during one year of follow-up. Within the first 7 days from
admission, each patient’s maximum biomarker value was
determined. The median values of the patient-level maxi-
mum were compared between the cases and controls by lin-
ear mixed effect (LME) models. Then, the patient-average
biomarker trajectories in 7 to 30 days from admission and
from 30 days onwards were compared between cases and
controls by LME models with nested random effects. Time
from index ACS event until each blood sample measure-
ment and a group variable (case/control) were entered as
fixed effects in the model, paired individuals as random
effects and serial GDF-15 measurements as the dependent
variable (model 1). Subsequently, we fitted multivariable
LME models with adjustment for age and gender (model
2), and with additional adjustment for admission diagnosis,
diabetes mellitus, smoking, hypertension, hypercholesterol-
emia, BMI, history of revascularization, history of myocar-
dial infarction and serum creatinine value (which was
measured at each sampling moment) (model 3). Values
were eventually backtransformed to present mean differen-
ces (95% confidence intervals [CI]) between cases and con-
trols on the linear scale. All data were analyzed with SPSS
(version 21) and R statistical software (version 3.5.1). All
statistical tests were two-tailed and p values <0.050 were
considered statistically significant.
Results
Baseline clinical characteristics are presented in Table 1.
The matching procedure appeared successful, as there were
no relevant differences between cases and controls, except
for admission diagnosis of STEMI (p value <0.001). Dur-
ing the first 7 days after the index ACS, GDF-15 levels
reached maximum values (median [IQR]) of 2436 [2286 to
4236] pg/mL in cases and 1804 [1207 to 3749] pg/mL in
the controls (p value 0.22). These levels slightly decreased
within the first 30 days, and the mean value within the 7 to
30 day period was 1908 pg/mL and 1590 pg/mL in cases
and controls, respectively. This mean difference of 318
(95% CI ranging from ¡215 to 1058) pg/mL was statisti-
cally nonsignificant (p value 0.26). From 30 days after the
index ACS onwards until 1-year follow-up, cases had sys-
tematically higher GDF-15 levels than controls (Table 2,
Table 1
Baseline clinical characteristics (n = 111)
Variable Cases (n = 37) Controls (n = 74) p value
Age (years) 67.9 § 11.7 66.3 § 11.2 0.79
Men 30 (81%) 60 (81%) 0.95
ST-segment elevation myocardial infarction 13 (35%) 42 (57%) <0.001
Non-ST-segment elevation myocardial infarction 18 (49%) 27 (37%) 0.17
Unstable angina pectoris 6 (16%) 5 (7%) 0.78
Smoker
Current 13 (35%) 25 (34%) 0.91
Former 11 (30%) 23 (31%) 0.97
Never 13 (35%) 26 (35%) 0.95
Diabetes mellitus 12 (32%) 26 (35%) 0.52
Hypertension 19 (51%) 40 (54%) 0.77
Hypercholesterolemia 17 (46%) 30 (41%) 0.81
Prior myocardial infarction 12 (32%) 23 (30%) 0.93
Prior percutaneous coronary intervention 11 (30%) 20 (27%) 0.88
Prior coronary artery bypass grafting 9 (24%) 10 (14%) 0.64
Prior stroke 8 (22%) 7 (10%) 0.78
Prior peripheral vascular disease 10 (27%) 13 (18%) 0.73
Values are mean § standard deviation or n (%). p values were obtained by the linear mixed model (continuous variable) or generalized linear mixed model
(categorical variable), whichever was appropriate.
Table 2
Mean GDF-15 (pg/mL) values in cases and controls in the 30 days to
1 year period after ACS admission
Cases Controls Mean difference (95% CI) p value
Model 1* 1780 1414 366 (26, 788) 0.034
Model 2y 1744 1415 329 (2, 732) 0.049
Model 3z 1704 1371 333 (68, 647) 0.013
CI = confidence interval.
* Unadjusted for patient characteristics.
yAdjusted for age and gender.
zAdjusted for age, gender, admission diagnosis, diabetes mellitus, smok-
ing, hypertension, hypercholesterolemia, BMI, history of revascularization,
history of myocardial infarction and serum creatinine value (measured at
each time-point).
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Figure 1). This difference remained significant after correc-
tion for age, gender and multiple cardiovascular risk factors
(p value 0.013). These findings are confirmed in strata
according to gender, diabetes mellitus, smoking, serum cre-
atinine value, and admission diagnosis (Supplemental
Tables 4−8). No differences were observed in GDF-15 lev-
els across the various subgroups (all p values for heteroge-
neity were >0.05).
An overview of the different variability parameters, cal-
culated for a selected amount of cases and controls, is pre-
sented in Table 3. With a CVa of 2%, both groups
displayed limited within-subject variability (CVi of 16.3 for
the cases and 11.5 for the controls), whereas the between-
subject variability showed larger variation (CVg of 73.1
for the cases and 62.0 for the controls). This is also shown
by a plot (Figure 2), which illustrates low within-subject
variability (CVi/[CVi + CVg] = 16% to 18%) and large
between-subject variability (CVg/(CVi + CVg) 82% to
84%) with a minimum of 579 pg/mL and a maximum of
9748 pg/mL. As could be expected from low within-subject
variability and high between-subject variability in both
groups, the II was low (below the threshold value of 0.6),
and thus individual reference values are preferred. Thereby
we found that the limits of change between subsequent
measurements (RCV) are allowed to range from ¡36% to
57% in cases and from ¡28% to 38% in controls.
Discussion
This is the first study to describe GDF-15 patterns in
post-ACS patients in great detail, utilizing a high-frequency
blood sampling design during 1 year. Four key lessons
were learned from our analysis. First, in individual patients,
after reaching a peak value in the first week after admission,
GDF-15 concentrations leveled off to levels that remain sta-
ble throughout 1-year follow-up. Second, importantly, there
was no steady or sudden change in GDF-15 level before a
recurrent event. Thus, no significant changes in GDF-15
values occurred after the initial post-ACS phase. Third,
patients who experienced a recurrent event had on average
26% higher GDF-15 levels than those who remained event-
free. Although the prognostic value of GDF-15 has already
Unadjusted p-value = 0.034
Adjusted p-value = 0.013
Figure 1. Serial measurements and temporal evolvement of GDF-15 (pg/mL) in cases (red) and controls (black). (Color version of figure is available online.)
The left graph shows the evolvement of GDF-15 since the index event (t = 0) until 1-year follow-up. The right graph shows the evolvement of GDF-15 before
the study endpoint (t = 0 in cases), or until the last blood sample moment (t = 0 in controls). The points represent measurements in individual patients. The
lines represent the group average values (bold lines) and the 95% confidence intervals (dashed lines), using linear mixed models with nested random effects.
Table 3
Parameters describing the biological variability of GDF-15 serial measurements 30 days after the acute coronary syndrome index event in both cases and
controls
Cases (n = 20) Controls (n = 46)
Average biomarker level (pg/mL), median [IQR] 1423 [1122−2594] 1317 [966−1705]
Analytical coefficient of variation (CVa) 2% 2%
Intra-individual coefficient of variation (CVi) 16.3 11.5
Inter-individual coefficient of variation (CVg) 73.1 62.0
Index of individuality (II) 0.2 0.2
Reference change value (RCV) 45% 32%
Reference change value, upper limit 57% 38%
Reference change value, lower limit ¡36% ¡28%
Parameters describing the biological variability of GDF-15, as calculated by formulas presented in the method section.
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been demonstrated by previous studies with one baseline
measurement, we additionally proved that repeated postdi-
scharge blood sampling of GDF-15 during 1 year might
help improve accurate prognostication. Fourth, within-
patient variability was much smaller than between-patient
variability, meaning that the number of repeated blood sam-
ples to obtain a patient-specific stable GDF-15 level can be
limited.
Considering the natural course of GDF-15 post-ACS in
our analysis, peak values are present in the first 7 days after
an ACS, whereafter it seems that GDF-15 subtly reaches a
stabilized phase without significant changes, especially
before a recurrent event. By the use of frequent serial meas-
urements, the stability of the marker in individual patients
on the long term was established. This finding is supported
by previous data in post-ACS patients, demonstrating that
GDF-15 concentrations show small alterations through the
first 72 hours of hospitalization and potentially several
months thereafter.3,4 The fact that GDF-15 concentration
levels remain significantly higher in patients who experi-
ence a recurrent event than in event-free patients over the
course of a year in our study without any level changes
around the event, suggests that GDF-15 is not merely a
reflection of extent of myocardial damage or infarct size,
but rather reflects severity of (chronic) atherosclerotic dis-
ease burden at any time point. This proposition is further
supported by findings with cardiovascular magnetic reso-
nance, demonstrating that GDF-15 is unrelated to infarct
size and myocardial area at risk 2 to 4 days after the index
event.9 Furthermore, GDF-15 concentrations on admission
seemed to be similar between NSTEMI and STEMI
patients, of whom more severe myocardial damage can be
expected.2,3 Thus, in support of our hypothesis, previous
studies do not indicate that GDF-15 solely mirrors tissue
damage.
With regard to prognostication, GDF-15 has been thor-
oughly investigated in clinical studies and shown to be an
independent prognostic marker of mortality and cardiovas-
cular events in both healthy individuals and CAD patients,
which is in accordance with our results.4−6,9−11 Specifi-
cally, a recent meta-analysis focused on ACS patients,
including 8 studies and 8,903 participants, showed a signifi-
cant hazard ratio (95% confidence interval) of 1.66 (1.47 to
1.87) on the association between GDF-15 and mortality or
recurrent MI.6 However, most studies performed blood
sampling only on admission at the onset of an ACS or at
discharge during the recovery phase of an ACS. As we
have demonstrated, initial GDF-15 peak values were
largely present in the first 7 days after the index ACS,
which is likely the expression of an acute phase reaction.
Therefore, single blood samples timed in the early phase
during the course of an ACS event may represent a peak
level, which does not clarify its prognostic implications on
long-term post-ACS. To our knowledge, only 2 clinical
studies have performed a limited number of serial GDF-15
measurements in post−NSTEMI patients.3,4 Wollert et al3
collected blood samples on admission and at 24, 48, and
72 hours in a subgroup of 399 patients, whereas Eggers
et al4 measured GDF-15 at baseline and after clinical stabi-
lization at 6 weeks, 3 months, 6 months in 950 patients.
Both studies found significant associations with respec-
tively 1-year and 5-year mortality at each time point. Along
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Figure 2. Graphical illustration of GDF-15 variability by displaying the distribution of GDF-15 measurements per patient 30 days after the ACS index event.
(Color version of figure is available online.)
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with our data with highly frequent blood sampling, we have
additionally demonstrated that obtained blood samples
within a course of 1 year post-ACS will provide compara-
ble prognostic information.
The biological variability of GDF-15 in ACS patients
has not been described so far. We found low within-subject
variability and high between-subject variability, which cor-
responds with findings from a study on the biovariability of
GDF-15 conducted in 41 patients with stable chronic sys-
tolic dysfunction.12 In this study, GDF-15 was measured at
4 blood sampling time points up until 3 months and showed
very little biological (within-)variation, whereas there was
an elevated between-individual variation (reflected by a
low II). Altogether, describing biomarker variability is war-
ranted to provide insight into the significance and interpre-
tation of a biomarker in clinical practice. Our results
indicate that changes in serial measurements of GDF-15 in
an individual who experienced an ACS, independently of
disease status (case or control), might be more useful than
population derived reference values.
The unique design and character of this study enabled us
to provide novel data on the temporal evolution and vari-
ability of GDF-15 post-ACS. Nevertheless, some limita-
tions warrant to be acknowledged. Due to the study design
and its observational character, this substudy is unable to
demonstrate causal inference. Whether GDF-15 merely
reflects CAD pathways, or directly contributes to coronary
pathophysiology remains unknown. Also, as opposed to
previous studies with large cohorts, we could not demon-
strate significant differences in GDF-15 levels between
cases and controls within the first 30 days. This is probably
due to a lack of power with a limited number of measure-
ments <30 days within a relatively small cohort. In line
with this, we are aware of the fact that our study comprises
a relatively small number of study patients and events. Fur-
ther, by acknowledging previous studies that investigated
the prognostic value of GDF-15 in large study populations,
our study encompassing an exceptional blood sampling fre-
quency method should rather be seen as hypothesis-testing
with an extension to existing knowledge.
In conclusion, with detailed analysis of the longitudinal
GDF-15 pattern post-ACS, we have demonstrated that
GDF-15 concentrations remain stable during follow-up
with limited within-individual variation. In patients who
eventually experience a recurrent event, GDF-15 is system-
atically elevated, independently of clinical risk factors and
serum creatinine. Thus, to enable risk stratification with
GDF-15 in post-ACS patients, blood sampling might be
used throughout the course of 1 year for prognostication,
whereas the number of repeated sampling moments might
be limited. Further exploration of the exact role of GDF-15
in risk stratifying post-ACS patients and deciding on clear
cut off points is warranted in future studies in order to
make accurate prognostications.
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